

ASPEN PHARMACARE HOLDINGS LIMITED  
(Incorporated in the Republic of South Africa) ("Aspen Holdings")  
Registration number: 1985/002935/06  
Share code: APN  
ISIN: ZAE000066692  
LEI: 635400ZYSN1IRD5QWQ94  
and its subsidiaries  
(collectively "Aspen" or "the Company")

## **AVAILABILITY OF INTEGRATED REPORT, B-BBEE VERIFICATION CERTIFICATE AND FURTHER NOTICE OF ANNUAL GENERAL MEETING**

### **1. POSTING OF AGM NOTICE AND AVAILABILITY OF REPORTING SUITE**

Shareholders are advised that the Company's Integrated Report for the year ended 30 June 2024 has been finalised and that the notice of the annual general meeting ("AGM") to be held at its Durban offices on 5 December 2024 is in the process of being posted to shareholders, along with a set of abbreviated annual financial statements ("AFS"). The following documents are now available on the Company's website [www.aspenpharma.com](http://www.aspenpharma.com) (at the following link <https://www.aspenpharma.com/investor-information/>):

- Integrated Report for the 2024 financial year;
- Notice of AGM and proxy in respect of the AGM to be held on 5 December 2024;
- Reports of the Aspen Audit & Risk and Social & Ethics committees for the 2024 financial year;
- Full AFS for the 2024 financial year (shareholders are referred to the No Change Statement and Notice of AGM as released on 2 October 2024); and
- Various other reports supplementary to the Integrated Report (collectively, the "Reporting Suite").

### **2. NOTICE OF AGM**

Further notice is hereby given that the 26<sup>th</sup> AGM of the shareholders of the Company will be held at Aspen Place, 9 Rydall Vale Park, Douglas Saunders Drive, La Lucia Ridge Office Park, Durban, Kwa-Zulu Natal, on Thursday, 5 December 2024 at 10:00. *Should you choose to attend the meeting in person, please contact the Company Secretary at [cossec@aspenpharma.com](mailto:cossec@aspenpharma.com) / 031 580 8600 by no later than 10:00 on Tuesday, 3 December 2024 in order for seating arrangements to be confirmed.*

The record date on which a person must be registered as a shareholder in the register of the Company for purposes of being entitled to attend and participate in, and speak and vote at, the meeting is Friday, 29 November 2024. Accordingly, the last day to trade in order to be registered in the register of members of the Company and therefore be eligible to participate in and vote at the AGM is Tuesday, 26 November 2024. Shareholders are requested, but are not obliged, to submit their completed forms of proxy to the Company's transfer secretaries (JSE Investor Services) before 10:00 on Tuesday, 3 December 2024.

Shareholders who, for whatever reason, experience postal delays and, as a consequence, do not receive the notice of the AGM in time to submit proxy forms to the Company's share transfer secretaries (JSE Investor Services) are requested to access the notice of AGM and the Reporting Suite referred to above on the Company's website [www.aspenpharma.com](http://www.aspenpharma.com). A printable version of the Reporting Suite in PDF format can also be emailed to shareholders upon request to the Company Secretary – [cossec@aspenpharma.com](mailto:cossec@aspenpharma.com) or +27 31 580 8600.

**Electronic participation**

Shareholders or their proxies or representatives may participate in (but not vote at) the meeting by way of telephone / video conference call, and if they wish to do so:

- Must contact the Company Secretary (by email at the address [cosec@aspenpharma.com](mailto:cosec@aspenpharma.com)) by no later than 10:00 on Friday 29 November 2024 in order to obtain the dial-in details / meeting link in order to participate in the meeting;
- Will be required to provide reasonably satisfactory identification; and
- Will be billed separately by their own service providers for the costs incurred in respect of their telephone / video call to participate in the meeting.

**3. BROAD-BASED BLACK ECONOMIC EMPOWERMENT CERTIFICATE**

Shareholders are hereby notified that in accordance with paragraph 16.21(g) and Appendix 1 to Section 11 of the JSE Listings Requirements, the Company has completed the B-BBEE verification process and has obtained a Level 4 B-BBEE rating. The verification certificate in terms of section 13G (2) of the Broad-Based Black Empowerment Amendment Act 46 of 2013, has been published and is available on the Company's website [www.aspenpharma.com](http://www.aspenpharma.com).

Durban  
25 October 2024

**Sponsor**  
**Investec Bank Limited**